Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product manufacturing services

CAR-T Digest - August 2020

15 September 2025: Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product manufacturing services

Spera Pharma and Mycenax Biotech have formed a strategic alliance to provide an integrated, turnkey solution for antibody-drug conjugates (ADCs) and bioconjugates, covering linker/payload synthesis, drug substance production, formulation, and aseptic fill-finish
The partnership combines Mycenax’s end-to-end biologics capabilities and KriSan Biotech’s ADC technologies with Spera Pharma’s CMC expertise, particularly in high-potent fill-finish services for ADCs
This collaboration aims to accelerate time-to-market for biopharma companies by offering a seamless, cost-effective, and scalable ADC development and manufacturing platform for global clients
Spera Pharma, spun off from Takeda’s CMC Research Division in 2017, is recognized for its technical excellence in complex drug development, GMP-compliant aseptic manufacturing, and integrated CMC solutions
Mycenax, an internationally audited biologics CDMO, has advanced its ADC platform with site-specific conjugation, multi-arm linkers, and novel linker designs, enhancing the partnership’s ability to deliver next-generation ADC solutions